Results 251 to 260 of about 65,496 (283)

Predictors of glycemic control with imeglimin for type 2 diabetes: Results of machine learning analyses using clinical trial data

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 214-226, February 2026.
Identifying patient characteristics predictive of treatment response is crucial for optimizing type 2 diabetes outcomes. Using data from three phase 2/3 imeglimin trials in Japan, this analysis applied machine learning to determine characteristics associated with HbA1c improvement.
Katsuhiko Hagi, Kazumasa Yoshida, Hirotaka Watada, Kohei Kaku, Kohjiro Ueki   +4 more
wiley   +1 more source

Efficacy and Safety of Vildagliptin Versus Other Dipeptidyl Peptidase 4 (DPP-4) Inhibitors in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials. [PDF]

Cureus
Selvaraj V.
europepmc   +1 more source

Comparative cardiovascular risk of sulfonylureas with low- and high-affinities for cardiac mitochondrial adenosine triphosphate-sensitive potassium channels versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A cohort study. [PDF]

Diabetes Obes Metab
Chen MH, Lin LY, Hung TY, Lin TC, Li CY, Lin TH, Chen YH, Liou JT, Wang MT.   +8 more
europepmc   +1 more source

Macrophage modulation with dipeptidyl peptidase-4 inhibitors: A new frontier for treating diabetic cardiomyopathy? [PDF]

World J Diabetes
Mohammadi S, Al-Harrasi A.
europepmc   +1 more source

Glucagon-like peptide-1 receptor analog use is associated with reduced thromboembolic events compared with dipeptidyl peptidase-4 inhibitors in rheumatoid arthritis patients: A global retrospective cohort study. [PDF]

Clin Rheumatol
Wang Q, Anthony DD.
europepmc   +1 more source

The Risk of Immune‐Mediated Skin Disease Under Dipeptidyl‐Peptidase IV Inhibitor: A Global Population‐Based Study

International Journal of Dermatology, Volume 65, Issue 2, Page 356-358, February 2026.
Noor Mruwat, Noga Givon‐Lavi, Ralf J. Ludwig, Khalaf Kridin   +3 more
wiley   +1 more source

Association between daily dose of dipeptidyl peptidase-4 inhibitors and change in glycated hemoglobin in patients with type 2 diabetes: interpretation of mixed-effects machine-learning models using electronic medical records. [PDF]

BMC Pharmacol Toxicol
Hayakawa T, Akimoto H, Nagashima T, Minagawa K, Takahashi Y, Asai S.   +5 more
europepmc   +1 more source

Correction to "Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial". [PDF]

Diabetes Obes Metab
europepmc   +1 more source